{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:22:21Z","timestamp":1785900141224,"version":"3.56.0"},"reference-count":270,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioMed Eng OnLine"],"DOI":"10.1186\/s12938-026-01531-8","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:34:03Z","timestamp":1769618043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted drug delivery strategies for oral cancer: the role of liposomes in drug delivery systems"],"prefix":"10.1186","volume":"25","author":[{"given":"Elham","family":"Saberian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parizad","family":"Ghanbarikondori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Zare-Zardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahyar","family":"Khanlari goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahere","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Mohammad","family":"Karimi Forood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meysam","family":"Ebrahimi far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"4","key":"1531_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.31557\/apjcb.2023.8.4.379-386","volume":"8","author":"E Saberian","year":"2023","unstructured":"Saberian E, Jen\u010da A, Petr\u00e1\u0161ov\u00e1 A, Jen\u010dov\u00e1 J, et al. Oral cancer at a glance. Asian Pac J Cancer Biol. 2023;8(4):379\u201386.","journal-title":"Asian Pac J Cancer Biol"},{"key":"1531_CR2","doi-asserted-by":"publisher","DOI":"10.4103\/ijpvm.ijpvm_403_18","author":"S Irani","year":"2020","unstructured":"Irani S. New insights into oral cancer\u2014risk factors and prevention: a review of literature. Int J Prevent Med. 2020. https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_403_18.","journal-title":"Int J Prevent Med"},{"issue":"7","key":"1531_CR3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.4065\/82.7.878","volume":"82","author":"D Kademani","year":"2007","unstructured":"Kademani D. Oral cancer. Mayo Clin Proc. 2007;82(7):878\u201387. https:\/\/doi.org\/10.4065\/82.7.878.","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"1531_CR4","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.7314\/APJCP.2014.15.15.5983","volume":"15","author":"B Gupta","year":"2014","unstructured":"Gupta B, Johnson NW. Emerging and established global lifestyle risk factors for cancer of the upper aero-digestive tract. Asian Pac J Cancer Prev. 2014;15(15):5983\u201391.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"32","key":"1531_CR5","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and increasing oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294\u2013301.","journal-title":"J Clin Oncol"},{"key":"1531_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194967","volume":"14","author":"M Gonzalez-Moles","year":"2022","unstructured":"Gonzalez-Moles M, Aguilar-Ruiz M, Ramos-Garc\u00eda P. Challenges in the early diagnosis of oral cancer, evidence gaps and strategies for improvement: a scoping review of systematic reviews. Cancers. 2022;14:194\u2013267. https:\/\/doi.org\/10.3390\/cancers14194967.","journal-title":"Cancers"},{"key":"1531_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12915","author":"J Webster","year":"2019","unstructured":"Webster J, Batstone M, Farah C. Missed opportunities for oral cancer screening in Australia. J Oral Pathol Med. 2019. https:\/\/doi.org\/10.1111\/jop.12915.","journal-title":"J Oral Pathol Med"},{"issue":"6","key":"1531_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.oraloncology.2010.03.009","volume":"46","author":"J Bagan","year":"2010","unstructured":"Bagan J, Sarri\u00f3n G, Jim\u00e9nez Y. Oral cancer: clinical features. Oral Oncol. 2010;46(6):414\u20137. https:\/\/doi.org\/10.1016\/j.oraloncology.2010.03.009.","journal-title":"Oral Oncol"},{"key":"1531_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203059","author":"A Rezapour","year":"2018","unstructured":"Rezapour A, Jahangiri R, Olyaeemanesh A, Kalaghchi B, Nouhi M, Nahvijou A. The economic burden of oral cancer in Iran. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0203059.","journal-title":"PLoS ONE"},{"issue":"6","key":"1531_CR10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/pharmaceutics16060802","volume":"16","author":"E Saberian","year":"2024","unstructured":"Saberian E, Jen\u02c7ca A, Petr\u00e1\u0161ov\u00e1 A, Zare-Zardini H, et al. Application of scaffold-based drug delivery in oral cancer treatment: a novel approach. Pharmaceutics. 2024;16(6):802. https:\/\/doi.org\/10.3390\/pharmaceutics16060802.","journal-title":"Pharmaceutics"},{"key":"1531_CR11","doi-asserted-by":"publisher","DOI":"10.37268\/mjphm\/vol.21\/no.2\/art.902","author":"M Khattak","year":"2021","unstructured":"Khattak M, Khan M, Khattak S, Khan Z, Haq Z, Saddki N. The experiences of oral cancer patients: a novel review. Malays J Public Health Med. 2021. https:\/\/doi.org\/10.37268\/mjphm\/vol.21\/no.2\/art.902.","journal-title":"Malays J Public Health Med"},{"key":"1531_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290364","author":"N Attaran","year":"2023","unstructured":"Attaran N, Sharma A, Morris M, Dudubo O, Macdonald M. What are the impacts of oral complications of cancer therapy on the quality of life of children? A protocol to update a scoping review. PLoS ONE. 2023. https:\/\/doi.org\/10.1371\/journal.pone.0290364.","journal-title":"PLoS ONE"},{"key":"1531_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/0976-237X.132336","volume":"5","author":"A Singh","year":"2014","unstructured":"Singh A, Bhatnagar A, Bansal R, Singh B. Oral rehabilitation of segmental mandibulectomy patient with osseointegrated dental implant. Contemp Clin Dent. 2014;5:209\u201312. https:\/\/doi.org\/10.4103\/0976-237X.132336.","journal-title":"Contemp Clin Dent"},{"issue":"4","key":"1531_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1515\/iss-2023-0031","volume":"8","author":"J Kr\u00f6plin","year":"2023","unstructured":"Kr\u00f6plin J, Reppenhagen J-C. Best practices and future challenges for treating oral cancer. Innov Surg Sci. 2023;8(4):215\u201320. https:\/\/doi.org\/10.1515\/iss-2023-0031.","journal-title":"Innov Surg Sci"},{"key":"1531_CR15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nrc1950","volume":"6","author":"S Bentzen","year":"2006","unstructured":"Bentzen S. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6:702\u201313. https:\/\/doi.org\/10.1038\/nrc1950.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1531_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1470-2045(03)01191-4","volume":"4","author":"H Stone","year":"2003","unstructured":"Stone H, Coleman C, Anscher M, McBride W. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4(9):529\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(03)01191-4.","journal-title":"Lancet Oncol"},{"key":"1531_CR17","doi-asserted-by":"publisher","DOI":"10.14710\/dmj.v12i3.37095","author":"F Jesslyn","year":"2023","unstructured":"Jesslyn F. An overview of chemotherapy side effects on patients with prostate cancer, bladder cancer, and testicular cancer at Haji Adam Malik General Hospital Medan from 2020\u20132022. Jurnal Kedokteran Diponegoro (Diponegoro Med J). 2023. https:\/\/doi.org\/10.14710\/dmj.v12i3.37095.","journal-title":"Jurnal Kedokteran Diponegoro (Diponegoro Med J)"},{"key":"1531_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11110","author":"H Chen","year":"2003","unstructured":"Chen H, Cantor A, Meyer J, Corcoran M, Grendys E, Cavanaugh D, et al. Can older patients with cancer tolerate chemotherapy? Cancer. 2003. https:\/\/doi.org\/10.1002\/cncr.11110.","journal-title":"Cancer"},{"key":"1531_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/froh.2020.00003","author":"RD Coletta","year":"2020","unstructured":"Coletta RD, Yeudall WA, Salo T. Grand challenges in oral cancers. Front Oral Health. 2020. https:\/\/doi.org\/10.3389\/froh.2020.00003.","journal-title":"Front Oral Health"},{"key":"1531_CR20","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2147\/IJN.S61670","volume":"9","author":"G Calixto","year":"2014","unstructured":"Calixto G, Bernegossi J, Fonseca-Santos B, Chorilli M. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomed. 2014;9:3719\u201335. https:\/\/doi.org\/10.2147\/IJN.S61670.","journal-title":"Int J Nanomed"},{"key":"1531_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25030715","author":"P Torre","year":"2020","unstructured":"Torre P, P\u00e9rez-Lorenzo M, Alc\u00e1zar-Garrido \u00c1, Flores A. Cell-based nanoparticle delivery systems for targeted cancer therapy: lessons from anti-angiogenesis treatments. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25030715.","journal-title":"Molecules"},{"key":"1531_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010007","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wu Y, Du H, Li Z, Bai X, Wu Y, et al. Nano-drug delivery systems in oral cancer therapy: recent developments and prospective. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics16010007.","journal-title":"Pharmaceutics"},{"key":"1531_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.618931","author":"M Zhang","year":"2020","unstructured":"Zhang M, Liang J, Yang Y, Liang H, Jia H, Li D. Current trends of targeted drug delivery for oral cancer therapy. Front Bioeng Biotechnol. 2020. https:\/\/doi.org\/10.3389\/fbioe.2020.618931.","journal-title":"Front Bioeng Biotechnol"},{"key":"1531_CR24","doi-asserted-by":"publisher","DOI":"10.1039\/c9nr03802g","author":"Q Song","year":"2019","unstructured":"Song Q, Jia J, Niu X, Zheng C, Zhao H, Sun L, et al. Oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy. Nanoscale. 2019. https:\/\/doi.org\/10.1039\/c9nr03802g.","journal-title":"Nanoscale"},{"issue":"2","key":"1531_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12291-024-01239-3","volume":"40","author":"P Ghanbarikondori","year":"2025","unstructured":"Ghanbarikondori P, Aliakbari RB, Saberian E, Jen\u010da A, Petr\u00e1\u0161ov\u00e1 A, et al. Enhancing cisplatin delivery via liposomal nanoparticles for oral cancer treatment. Indian J Clin Biochem. 2025;40(2):211\u20137.","journal-title":"Indian J Clin Biochem"},{"issue":"1","key":"1531_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jconrel.2011.07.013","volume":"156","author":"Y Wen","year":"2011","unstructured":"Wen Y, Gallego M, Nielsen L, Jorgensen L, Everland H, M\u00f8ller E, et al. Biodegradable nanocomposite microparticles as drug-delivering injectable cell scaffolds. J Control Release. 2011;156(1):11\u201320. https:\/\/doi.org\/10.1016\/j.jconrel.2011.07.013.","journal-title":"J Control Release"},{"key":"1531_CR27","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.2c10288","author":"J Luo","year":"2022","unstructured":"Luo J, Yang L, Chueng S, Conley B, Rathnam C, Lee K. Advanced drug delivery modulation via hybrid nanofibers enhances stem cell differentiation. ACS Appl Mater Interfaces. 2022. https:\/\/doi.org\/10.1021\/acsami.2c10288.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"4","key":"1531_CR28","first-page":"754","volume":"11","author":"S Semyari","year":"2021","unstructured":"Semyari S, Azizi S, Kundu D, Boroumandmoghaddam A, Moniri M, Ebrahimifar M, et al. A review of polybutyl cyanoacrylate nanoparticles for cancer drug delivery and targeting. J Nanostructures. 2021;11(4):754\u201371.","journal-title":"J Nanostructures."},{"key":"1531_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.07.004","author":"M Shahriari","year":"2019","unstructured":"Shahriari M, Zahiri M, Abnous K, Taghdisi S, Ramezani M, Alibolandi M. Enzyme responsive drug delivery systems in cancer treatment. J Control Release. 2019. https:\/\/doi.org\/10.1016\/j.jconrel.2019.07.004.","journal-title":"J Control Release"},{"key":"1531_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.cclet.2020.03.001","volume":"31","author":"Z Shi","year":"2020","unstructured":"Shi Z, Li Q, Mei L. pH-sensitive nanoscale materials as robust drug delivery systems for cancer therapy. Chin Chem Lett. 2020;31:1345\u201356. https:\/\/doi.org\/10.1016\/j.cclet.2020.03.001.","journal-title":"Chin Chem Lett"},{"key":"1531_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1450","author":"Y Lee","year":"2017","unstructured":"Lee Y, Thompson D. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017. https:\/\/doi.org\/10.1002\/wnan.1450.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"1531_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13020210.","journal-title":"Cancers"},{"key":"1531_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100715","volume":"53","author":"N Erin","year":"2020","unstructured":"Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial\u2013mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715. https:\/\/doi.org\/10.1016\/j.drup.2020.100715.","journal-title":"Drug Resist Updat"},{"key":"1531_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092053","volume":"13","author":"C Neophytou","year":"2021","unstructured":"Neophytou C, Panagi M, Stylianopoulos T, Papageorgis P. The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers. 2021;13:e00355. https:\/\/doi.org\/10.3390\/cancers13092053.","journal-title":"Cancers"},{"key":"1531_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00784","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, Meylan M, Reyni\u00e8s A, Saut\u00e8s-Fridman C, Fridman W. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00784.","journal-title":"Front Immunol"},{"key":"1531_CR36","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s11033-020-06054-6","volume":"48","author":"M Mughees","year":"2021","unstructured":"Mughees M, Sengupta A, Khowal S, Wajid S. Mechanism of tumour microenvironment in the progression and development of oral cancer. Mol Biol Rep. 2021;48:1773\u201386. https:\/\/doi.org\/10.1007\/s11033-020-06054-6.","journal-title":"Mol Biol Rep"},{"key":"1531_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00397","author":"S Brassart-Pasco","year":"2020","unstructured":"Brassart-Pasco S, Br\u00e9zillon S, Brassart B, Ramont L, Oudart J, Monboisse J. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.00397.","journal-title":"Front Oncol"},{"key":"1531_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7150\/jca.17648","volume":"8","author":"M Wang","year":"2017","unstructured":"Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761\u201373. https:\/\/doi.org\/10.7150\/jca.17648.","journal-title":"J Cancer"},{"issue":"2","key":"1531_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.yexcr.2013.12.029","volume":"325","author":"T Salo","year":"2014","unstructured":"Salo T, Vered M, Bello I, Nyberg P, Bitu C, Hurvitz A, et al. Insights into the role of components of the tumor microenvironment in oral carcinoma call for new therapeutic approaches. Exp Cell Res. 2014;325(2):58\u201364. https:\/\/doi.org\/10.1016\/j.yexcr.2013.12.029.","journal-title":"Exp Cell Res"},{"key":"1531_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220019","author":"M Anguiano","year":"2020","unstructured":"Anguiano M, Morales X, Castilla C, Pena A, Ederra C, Mart\u00ednez M, et al. The use of mixed collagen-Matrigel matrices of increasing complexity recapitulates the biphasic role of cell adhesion in cancer cell migration: ecm sensing, remodeling and forces at the leading edge of cancer invasion. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0220019.","journal-title":"PLoS ONE"},{"key":"1531_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151338","author":"G Ramos","year":"2016","unstructured":"Ramos G, Bernardi L, Lauxen I, Filho M, Horwitz A, Lamers M. Fibronectin modulates cell adhesion and signaling to promote single cell migration of highly invasive oral squamous cell carcinoma. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0151338.","journal-title":"PLoS ONE"},{"key":"1531_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104591","volume":"103","author":"Z Li","year":"2020","unstructured":"Li Z, Liu F, Kirkwood K. The p38\/MKP-1 signaling axis in oral cancer: impact of tumor-associated macrophages. Oral Oncol. 2020;103:104591. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104591.","journal-title":"Oral Oncol"},{"issue":"2","key":"1531_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/J.CANLET.2007.05.013","volume":"256","author":"D Raman","year":"2007","unstructured":"Raman D, Baugher P, Thu Y, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256(2):137\u201365. https:\/\/doi.org\/10.1016\/J.CANLET.2007.05.013.","journal-title":"Cancer Lett"},{"issue":"6","key":"1531_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/J.EJCA.2006.01.013","volume":"42","author":"L Yan","year":"2006","unstructured":"Yan L, Anderson G, DeWitte M, Nakada M. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer. 2006;42(6):793\u2013802. https:\/\/doi.org\/10.1016\/J.EJCA.2006.01.013.","journal-title":"Eur J Cancer"},{"key":"1531_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.arr.2017.03.008","volume":"36","author":"C Jackaman","year":"2017","unstructured":"Jackaman C, Tomay F, Duong L, Razak N, Pixley F, Metharom P, et al. Aging and cancer: the role of macrophages and neutrophils. Aging Res Rev. 2017;36:105\u201316. https:\/\/doi.org\/10.1016\/j.arr.2017.03.008.","journal-title":"Aging Res Rev"},{"key":"1531_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613114","author":"R Khouzam","year":"2021","unstructured":"Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin N, Buart S, Szczylik C, et al. Tumor hypoxia regulates immune escape\/invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2020.613114.","journal-title":"Front Immunol"},{"key":"1531_CR47","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"M Brahimi-Horn","year":"2007","unstructured":"Brahimi-Horn M, Chiche J, Pouyss\u00e9gur J. Hypoxia and cancer. J Mol Med. 2007;85:1301\u20137. https:\/\/doi.org\/10.1007\/s00109-007-0281-3.","journal-title":"J Mol Med"},{"key":"1531_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"W Wilson","year":"2011","unstructured":"Wilson W, Hay M. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393\u2013410. https:\/\/doi.org\/10.1038\/nrc3064.","journal-title":"Nat Rev Cancer"},{"key":"1531_CR49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/1535370220934038","volume":"245","author":"S Roy","year":"2020","unstructured":"Roy S, Kumaravel S, Sharma A, Duran C, Bayless K, Chakraborty S. Hypoxic tumor microenvironment: implications for cancer therapy. Exp Biol Med (Maywood). 2020;245:1073\u201386. https:\/\/doi.org\/10.1177\/1535370220934038.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7","key":"1531_CR50","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/J.ORALONCOLOGY.2007.08.013","volume":"44","author":"N Kassouf","year":"2008","unstructured":"Kassouf N, Thornhill M. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL, and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers. Oral Oncol. 2008;44(7):672\u201382. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2007.08.013.","journal-title":"Oral Oncol"},{"key":"1531_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa L, et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019;7:363\u201375. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0572.","journal-title":"Cancer Immunol Res"},{"key":"1531_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis M. Metabolites and the tumor microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21\u201332. https:\/\/doi.org\/10.1038\/s42255-020-00317-z.","journal-title":"Nat Metab"},{"issue":"5930","key":"1531_CR53","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u201333. https:\/\/doi.org\/10.1126\/science.1160809.","journal-title":"Science"},{"issue":"11","key":"1531_CR54","doi-asserted-by":"publisher","first-page":"9135","DOI":"10.1007\/s11033-020-05927-0","volume":"47","author":"K Karunakaran","year":"2020","unstructured":"Karunakaran K, Muniyan R. Genetic alterations and clinical dimensions of oral cancer: a review. Mol Biol Rep. 2020;47(11):9135\u201348. https:\/\/doi.org\/10.1007\/s11033-020-05927-0.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"1531_CR55","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.18632\/oncotarget.2850","volume":"6","author":"A Knopf","year":"2015","unstructured":"Knopf A, Lempart J, Bas M, Slotta-Huspenina J, et al. Oncogenes and tumor suppressor genes in squamous cell carcinoma of the tongue in young patients. Oncotarget. 2015;6(5):3443\u201351. https:\/\/doi.org\/10.18632\/oncotarget.2850.","journal-title":"Oncotarget"},{"key":"1531_CR56","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, et al. Current state-of-the-art and future trends in RAS-targeted cancer therapies. Nature Rev Clin Oncol. 2022;19:637\u201355.","journal-title":"Nature Rev Clin Oncol"},{"key":"1531_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/froh.2020.603160","volume":"1","author":"S Usman","year":"2020","unstructured":"Usman S, Jamal A, Teh MT, et al. Major molecular signaling pathways in oral cancer associated with therapeutic resistance. Front Oral Health. 2020;1:603160. https:\/\/doi.org\/10.3389\/froh.2020.603160.","journal-title":"Front Oral Health."},{"issue":"15","key":"1531_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153834","volume":"14","author":"M\u00c1 Gonz\u00e1lez-Moles","year":"2022","unstructured":"Gonz\u00e1lez-Moles M\u00c1, Warnakulasuriya S, et al. Hallmarks of cancer applied to oral and oropharyngeal carcinogenesis: a scoping review of the evidence gaps found in published systematic reviews. Cancers. 2022;14(15):3834. https:\/\/doi.org\/10.3390\/cancers14153834.","journal-title":"Cancers"},{"key":"1531_CR59","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200114114802","author":"R Emfietzoglou","year":"2020","unstructured":"Emfietzoglou R, Pachymanolis E, Piperi C. Impact of epigenetic alterations on the development of oral diseases. Curr Med Chem. 2020. https:\/\/doi.org\/10.2174\/0929867327666200114114802.","journal-title":"Curr Med Chem"},{"key":"1531_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235600","author":"H Mesgari","year":"2023","unstructured":"Mesgari H, Esmaelian S, Nasiri K, Ghasemzadeh S, Doroudgar P, Payandeh Z. Epigenetic regulation in oral squamous cell carcinoma microenvironment: a comprehensive review. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15235600.","journal-title":"Cancers"},{"key":"1531_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071506","author":"R Castilho","year":"2017","unstructured":"Castilho R, Squarize C, Almeida L. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18071506.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1531_CR62","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.oraloncology.2013.07.003","volume":"49","author":"L Feller","year":"2013","unstructured":"Feller L, Altini M, Lemmer J. Inflammation in the context of oral cancer. Oral Oncol. 2013;49(9):887\u201392. https:\/\/doi.org\/10.1016\/j.oraloncology.2013.07.003.","journal-title":"Oral Oncol"},{"issue":"1","key":"1531_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113099","volume":"23","author":"M Gonzalez-Moles","year":"2022","unstructured":"Gonzalez-Moles M, Pino C, Ramos-Garc\u00eda P. Hallmarks of cancer expression in oral lichen planus: a scoping review of systematic reviews and meta-analyses. Int J Mol Sci. 2022;23(1):e21399. https:\/\/doi.org\/10.3390\/ijms232113099.","journal-title":"Int J Mol Sci"},{"key":"1531_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13810","author":"J Aguirre-Urizar","year":"2021","unstructured":"Aguirre-Urizar J, Mendoza I, Warnakulasuriya S. Malignant transformation of oral leukoplakia: systematic review and meta-analysis of the last 5 years. Oral Dis. 2021. https:\/\/doi.org\/10.1111\/odi.13810.","journal-title":"Oral Dis"},{"key":"1531_CR65","doi-asserted-by":"publisher","first-page":"14489","DOI":"10.1002\/jcp.28252","volume":"234","author":"P Shadpour","year":"2019","unstructured":"Shadpour P, Zamani M, Aghaalikhani N, Rashtchizadeh N. Inflammatory cytokines in bladder cancer. J Cell Physiol. 2019;234:14489\u201399. https:\/\/doi.org\/10.1002\/jcp.28252.","journal-title":"J Cell Physiol"},{"key":"1531_CR66","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bjc.2014.579","volume":"112","author":"V Bagnardi","year":"2014","unstructured":"Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose\u2013response meta-analysis. Br J Cancer. 2014;112:580\u201393. https:\/\/doi.org\/10.1038\/bjc.2014.579.","journal-title":"Br J Cancer"},{"issue":"5","key":"1531_CR67","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/J.ORALONCOLOGY.2007.06.002","volume":"44","author":"R Muwonge","year":"2008","unstructured":"Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, et al. Role of tobacco smoking, chewing, and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case-control design using incident cancer cases. Oral Oncol. 2008;44(5):446\u201354. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2007.06.002.","journal-title":"Oral Oncol"},{"issue":"1","key":"1531_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.lfs.2012.10.009","volume":"92","author":"V Purohit","year":"2013","unstructured":"Purohit V, Rapaka R, Kwon O, Song B. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci. 2013;92(1):3\u20139. https:\/\/doi.org\/10.1016\/j.lfs.2012.10.009.","journal-title":"Life Sci"},{"key":"1531_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1940-6207.CAPR-17-0140","volume":"10","author":"S Khariwala","year":"2017","unstructured":"Khariwala S, Ma B, Ruszczak C, Carmella S, Lindgren B, Hatsukami D, et al. High level of tobacco carcinogen-derived DNA damage in oral cells is an independent predictor of oral\/head and neck cancer risk in smokers. Cancer Prev Res. 2017;10:507\u201313. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-17-0140.","journal-title":"Cancer Prev Res"},{"key":"1531_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11010145","author":"G Ferraguti","year":"2022","unstructured":"Ferraguti G, Terracina S, Petrella C, Greco A, Minni A, Lucarelli M, et al. Alcohol and head and neck cancer: updates on the role of oxidative stress, genetic, epigenetics, oral microbiota, antioxidants, and alkylating agents. Antioxidants. 2022. https:\/\/doi.org\/10.3390\/antiox11010145.","journal-title":"Antioxidants"},{"key":"1531_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061706","author":"N Yeo-Teh","year":"2018","unstructured":"Yeo-Teh N, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19061706.","journal-title":"Int J Mol Sci"},{"key":"1531_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/v14081764","author":"K Dust","year":"2022","unstructured":"Dust K, Carpenter M, Chen J, Grant C, McCorrister S, Westmacott G, et al. Human papillomavirus 16 E6 and E7 oncoproteins alter the abundance of proteins associated with DNA damage response, immune signaling, and epidermal differentiation. Viruses. 2022. https:\/\/doi.org\/10.3390\/v14081764.","journal-title":"Viruses"},{"key":"1531_CR73","doi-asserted-by":"publisher","unstructured":"Gleich L, Biddinger P, Pavelic Z, Gluckman J. Tumor angiogenesis in T1 oral cavity squamous cell carcinoma: role in predicting tumor aggressiveness. Head Neck; 1996. https:\/\/doi.org\/10.1002\/(SICI)1097-0347(199607\/08)18:4<343:AID-HED5>3.0.CO;2-Y.","DOI":"10.1002\/(SICI)1097-0347(199607\/08)18:4<343:AID-HED5>3.0.CO;2-Y"},{"issue":"6","key":"1531_CR74","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1368-8375(98)00054-2","volume":"34","author":"D Ravi","year":"1998","unstructured":"Ravi D, Ramadas K, Mathew B, Nalinakumari K, Nair M, Pillai M. Angiogenesis during tumor progression in the oral cavity is related to reduced apoptosis and high tumor cell proliferation. Oral Oncol. 1998;34(6):543\u20138. https:\/\/doi.org\/10.1016\/S1368-8375(98)00054-2.","journal-title":"Oral Oncol"},{"issue":"1","key":"1531_CR75","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1368-8375(99)00059-7","volume":"36","author":"Y Michi","year":"2000","unstructured":"Michi Y, Morita I, Amagasa T, Murota S. Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR\/flk-1 expression in endothelial cells. Oral Oncol. 2000;36(1):81\u20138. https:\/\/doi.org\/10.1016\/S1368-8375(99)00059-7.","journal-title":"Oral Oncol"},{"issue":"4","key":"1531_CR76","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/ER.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581\u2013611. https:\/\/doi.org\/10.1210\/ER.2003-0027.","journal-title":"Endocr Rev"},{"key":"1531_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12017","author":"K Yeung","year":"2016","unstructured":"Yeung K, Yang J. Epithelial\u2013mesenchymal transition in tumor metastasis. Mol Oncol. 2016. https:\/\/doi.org\/10.1002\/1878-0261.12017.","journal-title":"Mol Oncol"},{"key":"1531_CR78","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/ijc.33352","volume":"148","author":"Z Ling","year":"2020","unstructured":"Ling Z, Cheng B, Tao X. Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: challenges and opportunities. Int J Cancer. 2020;148:1548\u201361. https:\/\/doi.org\/10.1002\/ijc.33352.","journal-title":"Int J Cancer"},{"issue":"2","key":"1531_CR79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/J.CRITREVONC.2003.09.001","volume":"50","author":"G Klein","year":"2004","unstructured":"Klein G, Vellenga E, Fraaije M, Kamps W, Bont D. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g., acute leukemia. Crit Rev Oncol Hematol. 2004;50(2):87\u2013100. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2003.09.001.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1531_CR80","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52\u201367. https:\/\/doi.org\/10.1016\/j.cell.2010.03.015.","journal-title":"Cell"},{"key":"1531_CR81","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.7150\/thno.14858","volume":"6","author":"D Liu","year":"2016","unstructured":"Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential. Theranostics. 2016;6:1306\u201323. https:\/\/doi.org\/10.7150\/thno.14858.","journal-title":"Theranostics"},{"issue":"5","key":"1531_CR82","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/wnan.1389","volume":"8","author":"M Karimi","year":"2016","unstructured":"Karimi M, Eslami M, Sahandi-Zangabad P, Mirab F, Farajisafiloo N, Shafaei Z, et al. Ph-sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(5):696\u2013716. https:\/\/doi.org\/10.1002\/wnan.1389.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"33","key":"1531_CR83","doi-asserted-by":"publisher","first-page":"21107","DOI":"10.1021\/acsami.6b00371","volume":"8","author":"M Karimi","year":"2016","unstructured":"Karimi M, Zangabad P, Ghasemi A, Amiri M, Bahrami M, Malekzad H, et al. Temperature-Responsive smart nanocarriers for delivery of therapeutic agents: applications and recent advances. ACS Appl Mater Interfaces. 2016;8(33):21107\u201333. https:\/\/doi.org\/10.1021\/acsami.6b00371.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1531_CR84","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jcis.2020.09.073","volume":"583","author":"S Wang","year":"2020","unstructured":"Wang S, Liu H, Wu D, Wang X. Temperature and pH dual-stimuli-responsive phase-change microcapsules for multipurpose applications in smart drug delivery. J Colloid Interface Sci. 2020;583:470\u201386. https:\/\/doi.org\/10.1016\/j.jcis.2020.09.073.","journal-title":"J Colloid Interface Sci"},{"key":"1531_CR85","doi-asserted-by":"publisher","unstructured":"Ghaffar A, Yameen B, Latif M, Malik MI. pH-sensitive drug delivery systems, 2020.\u00a0https:\/\/doi.org\/10.1016\/b978-0-12-816960-5.00014-8.","DOI":"10.1016\/b978-0-12-816960-5.00014-8."},{"key":"1531_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122712","author":"S Shahriar","year":"2022","unstructured":"Shahriar S, Andrabi S, Islam F, An J, Schindler S, Matis M, et al. Next-generation 3D scaffolds for nano-based chemotherapy delivery and cancer treatment. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14122712.","journal-title":"Pharmaceutics"},{"key":"1531_CR87","doi-asserted-by":"publisher","DOI":"10.1007\/s40820-020-00482-6","author":"W Mu","year":"2020","unstructured":"Mu W, Chu Q, Liu Y, Zhang N. A review on nano-based drug delivery system for cancer chemomoimmunotherapy. Nano-Micro Lett. 2020. https:\/\/doi.org\/10.1007\/s40820-020-00482-6.","journal-title":"Nano-Micro Lett"},{"key":"1531_CR88","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.2147\/IJN.S168053","volume":"13","author":"R Kalaydina","year":"2018","unstructured":"Kalaydina R, Bajwa K, Qorri B, Decarlo A, Szewczuk M. Recent advances in \u201csmart\u201d delivery systems for extended drug release in cancer therapy. Int J Nanomed. 2018;13:4727\u201345. https:\/\/doi.org\/10.2147\/IJN.S168053.","journal-title":"Int J Nanomed"},{"key":"1531_CR89","doi-asserted-by":"publisher","first-page":"21365","DOI":"10.1039\/d3ra02969g","volume":"13","author":"L Hong","year":"2023","unstructured":"Hong L, Li W, Li Y, Yin S. Nanoparticle-based drug delivery systems targeting cancer cell surfaces. RSC Adv. 2023;13:21365\u201382. https:\/\/doi.org\/10.1039\/d3ra02969g.","journal-title":"RSC Adv"},{"key":"1531_CR90","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bmt.2023.09.001","volume":"5","author":"K Elumalai","year":"2024","unstructured":"Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Technol. 2024;5:109\u201322.","journal-title":"Biomed Technol"},{"key":"1531_CR91","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Chehelgerdi M, Allela OQ, Pecho RD, et al. Progress in the development of nanotechnology for targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22:169.","journal-title":"Mol Cancer"},{"key":"1531_CR92","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","volume":"7","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, Yanyan Xu, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193. https:\/\/doi.org\/10.3389\/fmolb.2020.00193.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"1531_CR93","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cbdd.1278636","volume":"88","author":"D Poy","year":"2016","unstructured":"Poy D, Akbarzadeh A, Ebrahimi Shahmabadi H, Ebrahimifar M, Farhangi A, Farahnak Zarabi M, et al. Preparation, characterization, and cytotoxic effects of liposomal nanoparticles containing cisplatin: an in vitro study. Chem Biol Drug Des. 2016;88(4):568\u201373. https:\/\/doi.org\/10.1111\/cbdd.1278636.","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"1531_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.22034\/APJCP.2017.18.1.6537","volume":"18","author":"M Ebrahimifar","year":"2017","unstructured":"Ebrahimifar M, Roudsari MH, Kazemi SM, Shahmabadi HE, Kanaani L, Alavi SA, et al. Enhancing effects of curcumin on the cytotoxicity of paclitaxel, methotrexate, and vincristine in gastric cancer cells. Asian Pacific J Cancer Prevent APJCP. 2017;18(1):65\u20138. https:\/\/doi.org\/10.22034\/APJCP.2017.18.1.6537.","journal-title":"Asian Pacific J Cancer Prevent APJCP."},{"issue":"3","key":"1531_CR95","doi-asserted-by":"publisher","first-page":"629","DOI":"10.22034\/APJCP.2017.18.3.62938","volume":"18","author":"N Mohamadi","year":"2017","unstructured":"Mohamadi N, Kazemi SM, Mohammadian M, Milani AT, Moradi Y, Yasemi M, et al. Toxicity of cisplatin-loaded polybutyl cyanoacrylate nanoparticles in a brain cancer cell line: anionic polymerization results. Asian Pacific J Cancer Prevent APJCP. 2017;18(3):629\u201332. https:\/\/doi.org\/10.22034\/APJCP.2017.18.3.62938.","journal-title":"Asian Pacific J Cancer Prevent APJCP."},{"issue":"8","key":"1531_CR96","first-page":"3835","volume":"17","author":"B Amiri","year":"2016","unstructured":"Amiri B, Ebrahimi-Far M, Saffari Z, Akbarzadeh A, Soleimani E, Chiani M. Preparation, characterization and cytotoxicity of silibinin-containing nanoniosomes in T47D human breast carcinoma cells. Asian Pac J Cancer Prev. 2016;17(8):3835\u201340.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1531_CR97","doi-asserted-by":"publisher","first-page":"102662","DOI":"10.1016\/j.nano.2023.102662","volume":"49","author":"K Vyas","year":"2023","unstructured":"Vyas K, Rathod M, Patel MM. Insight on nano drug delivery systems with targeted therapy in treatment of oral cancer. Nanomed Nanotechnol Biol Med. 2023;49:102662. https:\/\/doi.org\/10.1016\/j.nano.2023.102662.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"17","key":"1531_CR98","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.3390\/molecules27175436","volume":"27","author":"G Ioele","year":"2022","unstructured":"Ioele G, Chieffallo M, Occhiuzzi MA, et al. Anticancer drugs: recent strategies to improve stability profile, pharmacokinetic and pharmacodynamic properties. Molecules. 2022;27(17):5436. https:\/\/doi.org\/10.3390\/molecules27175436.","journal-title":"Molecules"},{"issue":"1","key":"1531_CR99","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/cancers15010268","volume":"15","author":"A Sachdeva","year":"2023","unstructured":"Sachdeva A, Dhawan D, Jain GK, et al. Novel strategies for the augmentation of bioavailability and efficacy of natural products in oral cancer. Cancers (Basel). 2023;15(1):268. https:\/\/doi.org\/10.3390\/cancers15010268.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1531_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03639045.2023.2182124","volume":"49","author":"E Shukla","year":"2023","unstructured":"Shukla E, Kara DD, Katikala T, et al. Self-nanoemulsifying drug delivery systems (SNEDDS) of anti-cancer drugs: a multifaceted nanoplatform for the enhancement of oral bioavailability. Drug Dev Ind Pharm. 2023;49(1):1\u201316. https:\/\/doi.org\/10.1080\/03639045.2023.2182124.","journal-title":"Drug Dev Ind Pharm"},{"issue":"11","key":"1531_CR101","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1080\/17425247.2023.2289586","volume":"20","author":"F Laffleur","year":"2023","unstructured":"Laffleur F, Mayer AH. Oral nanoparticulate drug delivery systems for treating intestinal bowel disease and colorectal cancer. Expert Opin Drug Deliv. 2023;20(11):1595\u2013607. https:\/\/doi.org\/10.1080\/17425247.2023.2289586.","journal-title":"Expert Opin Drug Deliv"},{"key":"1531_CR102","unstructured":"Moidul M et al. Emerging trends in novel drug delivery systems for the effective treatment of oral cancer. Current Cancer Therapy Rev, 2024."},{"key":"1531_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030627","author":"W Boogaard","year":"2022","unstructured":"Boogaard W, Komninos D, Vermeij W. Chemotherapy side-effects: not all DNA damage is equal. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14030627.","journal-title":"Cancers"},{"key":"1531_CR104","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.4317\/jced.51337","volume":"6","author":"B Chaveli-L\u00f3pez","year":"2014","unstructured":"Chaveli-L\u00f3pez B. Oral toxicity produced by chemotherapy: a systematic review. J Clin Exp Dent. 2014;6:e81\u201390. https:\/\/doi.org\/10.4317\/jced.51337.","journal-title":"J Clin Exp Dent"},{"issue":"7","key":"1531_CR105","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/pharmaceutics11070302","volume":"11","author":"F Ketabat","year":"2019","unstructured":"Ketabat F, Pundir M, Mohabatpour F, et al. Controlled drug delivery systems for oral cancer treatment\u2014current status and future perspectives. Pharmaceutics. 2019;11(7):302. https:\/\/doi.org\/10.3390\/pharmaceutics11070302.","journal-title":"Pharmaceutics"},{"issue":"Suppl 2","key":"1531_CR106","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/J.EJON.2005.09.003","volume":"9","author":"P Ravasco","year":"2005","unstructured":"Ravasco P. Aspects of taste and compliance in patients with cancer. Eur J Oncol Nurs. 2005;9(Suppl 2):S84-91. https:\/\/doi.org\/10.1016\/J.EJON.2005.09.003.","journal-title":"Eur J Oncol Nurs"},{"key":"1531_CR107","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/03639045.2017.1290865","volume":"43","author":"J McConville","year":"2017","unstructured":"McConville J. Current developments in oral drug administration. Drug Dev Ind Pharm. 2017;43:699\u2013699. https:\/\/doi.org\/10.1080\/03639045.2017.1290865.","journal-title":"Drug Dev Ind Pharm"},{"key":"1531_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.618411","author":"M Alqahtani","year":"2021","unstructured":"Alqahtani M, Kazi M, Alsenaidy M, Ahmad M. Advances in oral drug delivery. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.618411.","journal-title":"Front Pharmacol"},{"key":"1531_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101712","author":"K Shailesh","year":"2020","unstructured":"Shailesh K, Vaishali L. Review on: alternatives to large dosage forms for ease of swallowing. J Drug Deliv Sci Technol. 2020. https:\/\/doi.org\/10.1016\/j.jddst.2020.101712.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1531_CR110","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/BF02849950","volume":"22","author":"A Wertheimer","year":"2005","unstructured":"Wertheimer A, Santella T, Finestone A, Levy R. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther. 2005;22:559\u201377. https:\/\/doi.org\/10.1007\/BF02849950.","journal-title":"Adv Ther"},{"key":"1531_CR111","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12247-019-09407-2","volume":"15","author":"N Drumond","year":"2020","unstructured":"Drumond N. Future perspectives for patient-centric pharmaceutical drug product design regarding solid oral dosage forms. J Pharm Innov. 2020;15:318\u201324. https:\/\/doi.org\/10.1007\/s12247-019-09407-2.","journal-title":"J Pharm Innov"},{"issue":"6","key":"1531_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17488","volume":"9","author":"TC Ezike","year":"2023","unstructured":"Ezike TC, Okpala US, Onoja UL, et al. Advances in drug-delivery systems, challenges and future directions. Heliyon. 2023;9(6):e17488. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17488.","journal-title":"Heliyon"},{"issue":"5","key":"1531_CR113","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4155\/tde.15.5","volume":"6","author":"S Nguyen","year":"2015","unstructured":"Nguyen S, Hiorth M. Advanced drug delivery systems for local treatment of the oral cavity. Ther Deliv. 2015;6(5):595\u2013608. https:\/\/doi.org\/10.4155\/tde.15.5.","journal-title":"Ther Deliv"},{"key":"1531_CR114","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.biomaterials.2016.10.016","volume":"112","author":"S Qin","year":"2017","unstructured":"Qin S, Zhang A, Cheng S, Rong L, Zhang X. Drug self-delivery systems for cancer therapy. Biomaterials. 2017;112:234\u201347. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.10.016.","journal-title":"Biomaterials"},{"key":"1531_CR115","doi-asserted-by":"publisher","DOI":"10.26689\/ijgpn.v2i2.7436","author":"M Zubair","year":"2024","unstructured":"Zubair M, Riaz M, Kiani MN, Aslam HM, Fatima AE, Sultan HM, et al. Application of nanotechnology in targeted drug delivery and nontoxicity. IJGPN. 2024. https:\/\/doi.org\/10.26689\/ijgpn.v2i2.7436.","journal-title":"IJGPN"},{"key":"1531_CR116","doi-asserted-by":"publisher","unstructured":"Laksiri W, Imalka M, Munaweera N (2024) Nanotechnology for drug design and drug delivery. https:\/\/doi.org\/10.2174\/9789815238815124010005.","DOI":"10.2174\/9789815238815124010005"},{"key":"1531_CR117","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s469572","author":"N Wathoni","year":"2024","unstructured":"Wathoni N, Herdiana Y, Suhandi C, Mohammed AF, El-Rayyes A, Narsa AC. Chitosan\/alginate-based nanoparticles for antibacterial agents delivery. Int J Nanomedicine. 2024. https:\/\/doi.org\/10.2147\/ijn.s469572.","journal-title":"Int J Nanomedicine"},{"key":"1531_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.nanoso.2024.101177","author":"V Jadhav","year":"2024","unstructured":"Jadhav V, Roy A, Kaur K, Roy A, Sharma K, Verma R, et al. Current advances in functional nanomaterials for drug delivery systems. Nano-Struct Nano-Obj. 2024. https:\/\/doi.org\/10.1016\/j.nanoso.2024.101177.","journal-title":"Nano-Struct Nano-Obj"},{"key":"1531_CR119","doi-asserted-by":"publisher","DOI":"10.2174\/1381612828666220422085702","author":"H Fatima","year":"2022","unstructured":"Fatima H, Naz MY, Shukrullah S, Aslam H, Ullah S, Assiri MA. A review of multifunction smart nanoparticle-based drug delivery systems. Current Pharm Des. 2022. https:\/\/doi.org\/10.2174\/1381612828666220422085702.","journal-title":"Current Pharm Des"},{"key":"1531_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01642-x","author":"S Leming","year":"2023","unstructured":"Leming S, Hongmei L, Yanqi Ye, Yang L, Rehmat I, Sumin T, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01642-x.","journal-title":"Signal Transduct Target Ther"},{"key":"1531_CR121","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c10732","author":"T Kim","year":"2024","unstructured":"Kim T, Han HS, Yang K, Kim YM, Nam K, Park KH, et al. Nanoengineered polymeric RNA nanoparticles for controlled biodistribution and efficient targeted cancer therapy. ACS Nano. 2024. https:\/\/doi.org\/10.1021\/acsnano.3c10732.","journal-title":"ACS Nano"},{"key":"1531_CR122","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202308446","author":"L Wang","year":"2023","unstructured":"Wang L, Quine S, Frickenstein AN, Lee M, Yang W, Sheth VM, et al. Exploring and analyzing the systemic delivery barriers for nanoparticles. Adv Funct Mater. 2023. https:\/\/doi.org\/10.1002\/adfm.202308446.","journal-title":"Adv Funct Mater"},{"key":"1531_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6502","author":"A Sumel","year":"2023","unstructured":"Sumel A, Ashish G, Afzal H, Arshad F, Prashant K, Farhad T-H. Nanodelivery systems: an efficient and target-specific approach for drug-resistant cancers. Cancer Med. 2023. https:\/\/doi.org\/10.1002\/cam4.6502.","journal-title":"Cancer Med"},{"key":"1531_CR124","doi-asserted-by":"publisher","DOI":"10.2174\/9789815179422123080010","author":"B Hande","year":"2023","unstructured":"Hande B, G\u00fcliz A. Nanoparticle targeting strategies in cancer therapy. Recent Adv Biotechnol. 2023. https:\/\/doi.org\/10.2174\/9789815179422123080010.","journal-title":"Recent Adv Biotechnol"},{"key":"1531_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-00994-y","author":"WH Abuwatfa","year":"2024","unstructured":"Abuwatfa WH, Pitt WG, Husseini GA. Scaffold-based 3D cell culture models in cancer research. J Biomed Sci. 2024. https:\/\/doi.org\/10.1186\/s12929-024-00994-y.","journal-title":"J Biomed Sci"},{"key":"1531_CR126","doi-asserted-by":"publisher","DOI":"10.1021\/acsanm.4c00421","author":"S Shurui","year":"2024","unstructured":"Shurui S, Kaiyu Fu, Shuai H, Yang C, Yunhan C, Xin Hu, et al. Cancer cell membrane-coated nanoparticles for the treatment of oral tongue squamous cell carcinoma by combining photothermal\/photodynamic therapy and autophagy inhibition. ACS Appl Nano Mater. 2024. https:\/\/doi.org\/10.1021\/acsanm.4c00421.","journal-title":"ACS Appl Nano Mater"},{"key":"1531_CR127","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v14i7.6644","author":"M Ardhendu","year":"2024","unstructured":"Ardhendu M. Platinum nanoparticles as delivery system in combating various diseases. J Drug Deliv Therap. 2024. https:\/\/doi.org\/10.22270\/jddt.v14i7.6644.","journal-title":"J Drug Deliv Therap"},{"key":"1531_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.nxmate.2024.100128","author":"H Ghazal","year":"2024","unstructured":"Ghazal H, Waqar A, Yaseen F, Shahid M, Sultana M, Tariq M, et al. The role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment. Next Mater. 2024. https:\/\/doi.org\/10.1016\/j.nxmate.2024.100128.","journal-title":"Next Mater"},{"key":"1531_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030329","author":"P Patel","year":"2024","unstructured":"Patel P, Garala K, Singh S, Prajapati BG, Chittasupho C. Lipid-based nanoparticles in delivering bioactive compounds for improving therapeutic efficacy. Pharmaceuticals. 2024. https:\/\/doi.org\/10.3390\/ph17030329.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"1531_CR130","doi-asserted-by":"publisher","first-page":"9638","DOI":"10.1021\/acsnano.5b04520","volume":"9","author":"H Zhao","year":"2015","unstructured":"Zhao H, Feng H, Liu D, Liu J, Ji N, Chen F, et al. Self-assembling monomeric nucleoside molecular nanoparticles loaded with 5-FU enhancing therapeutic efficacy against oral cancer. ACS Nano. 2015;9(10):9638\u201351. https:\/\/doi.org\/10.1021\/acsnano.5b04520.","journal-title":"ACS Nano"},{"key":"1531_CR131","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2022-0208","author":"Y Yu","year":"2023","unstructured":"Yu Y, Bu F, Yu Y, Yan C, Wu Z, Li Y. 5-fluorouracil-caffeic acid cocrystal delivery agent with long-term and synergistic high-performance antitumor effects. Nanomedicine. 2023. https:\/\/doi.org\/10.2217\/nnm-2022-0208.","journal-title":"Nanomedicine"},{"key":"1531_CR132","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.2147\/IJN.S165210","volume":"13","author":"N Muhamad","year":"2018","unstructured":"Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional\/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine. 2018;13:3921\u201335. https:\/\/doi.org\/10.2147\/IJN.S165210.","journal-title":"Int J Nanomedicine"},{"key":"1531_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091919","author":"T Yang","year":"2022","unstructured":"Yang T, Zhai J, Hu D, Yang R, Wang G, Li Y, et al. \u201cTargeting Design\u201d of nanoparticles in tumor therapy. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14091919.","journal-title":"Pharmaceutics"},{"key":"1531_CR134","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/ace8de","author":"D Bhattacharya","year":"2023","unstructured":"Bhattacharya D, Sakhare K, Dhiman C, Ansari A, Kundu T, Narayan K, et al. Delivery of chemotherapeutic drug targeting folate receptor to oral cancer cells using functionalized carbon nanospheres. Biomed Mater. 2023. https:\/\/doi.org\/10.1088\/1748-605X\/ace8de.","journal-title":"Biomed Mater"},{"key":"1531_CR135","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1517\/17425247.5.3.309","volume":"5","author":"X Zhao","year":"2008","unstructured":"Zhao X, Li H, Lee R. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008;5:309\u201319. https:\/\/doi.org\/10.1517\/17425247.5.3.309.","journal-title":"Expert Opin Drug Deliv"},{"key":"1531_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.110341","volume":"107","author":"B Farran","year":"2020","unstructured":"Farran B, Montenegro R, Kasa P, Pavitra E, Huh Y, Han Y, et al. Folate-conjugated nanovehicles: strategies for cancer therapy. Mater Sci Eng, C Mater Biol Appl. 2020;107:110341. https:\/\/doi.org\/10.1016\/j.msec.2019.110341.","journal-title":"Mater Sci Eng, C Mater Biol Appl"},{"key":"1531_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207693","author":"H Kim","year":"2023","unstructured":"Kim H, Villareal L, Liu Z, Haneef M, Falcon D, Martin D, et al. Transferrin receptor-mediated iron uptake promotes colon tumorigenesis. Adv Sci. 2023. https:\/\/doi.org\/10.1002\/advs.202207693.","journal-title":"Adv Sci"},{"key":"1531_CR138","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/aps.2017.45","volume":"38","author":"Y Cui","year":"2017","unstructured":"Cui Y, Xu Q, Davoodi P, Wang D, Wang C. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin. Acta Pharmacol Sin. 2017;38:943\u201353. https:\/\/doi.org\/10.1038\/aps.2017.45.","journal-title":"Acta Pharmacol Sin"},{"key":"1531_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511888","author":"J C\u00edvico-Ortega","year":"2023","unstructured":"C\u00edvico-Ortega J, Gonz\u00e1lez-Ruiz I, Ramos-Garc\u00eda P, Cruz-Granados D, Samayoa-Descamps V, Gonzalez-Moles M. Prognostic and clinicopathological significance of epidermal growth factor receptor (EGFR) expression in oral squamous cell carcinoma: systematic review and meta-analysis. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241511888.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1531_CR140","first-page":"4164","volume":"5","author":"W Xia","year":"1999","unstructured":"Xia W, Lau Y, Zhang H, Xiao F, Johnston D, Liu A, et al. Combination of EGFR, HER-2\/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family member. Clin Cancer Res. 1999;5(12):4164\u201374.","journal-title":"Clin Cancer Res"},{"key":"1531_CR141","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2023.2295803","author":"A Al-taie","year":"2023","unstructured":"Al-taie A, B\u00fclb\u00fcl E. A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches. J Drug Target. 2023. https:\/\/doi.org\/10.1080\/1061186X.2023.2295803.","journal-title":"J Drug Target"},{"key":"1531_CR142","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-8722-5-70","volume":"5","author":"M Firer","year":"2012","unstructured":"Firer M, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012;5:70\u201370. https:\/\/doi.org\/10.1186\/1756-8722-5-70.","journal-title":"J Hematol Oncol"},{"key":"1531_CR143","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18:533\u201348. https:\/\/doi.org\/10.1038\/s41568-018-0038-z.","journal-title":"Nat Rev Cancer"},{"key":"1531_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050640","author":"J Yoo","year":"2019","unstructured":"Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11050640.","journal-title":"Cancers"},{"key":"1531_CR145","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.36862","author":"M Alipour","year":"2019","unstructured":"Alipour M, Baneshi M, Hosseinkhani S, Mahmoudi R, Arabzadeh A, Akrami M, et al. Recent progress in biomedical applications of RGD-based ligands: from precise cancer theranostic to biomaterial engineering: a systematic review. J Biomed Mater Res Part A. 2019. https:\/\/doi.org\/10.1002\/jbm.a.36862.","journal-title":"J Biomed Mater Res Part A"},{"key":"1531_CR146","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/1538-7445.AM2013-4339","volume":"73","author":"D Shan","year":"2013","unstructured":"Shan D, Cai P, Prasad P, Rauth A, Wu X. Abstract 4339: RGD-conjugated nanoparticles for targeted inhibition of adhesion and migration of integrin \u03b1v\u03b23-overexpressing breast cancer cells. Cancer Res. 2013;73:4339\u20134339. https:\/\/doi.org\/10.1158\/1538-7445.AM2013-4339.","journal-title":"Cancer Res"},{"key":"1531_CR147","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax6337","author":"J Jaynes","year":"2020","unstructured":"Jaynes J, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aax6337.","journal-title":"Sci Transl Med"},{"key":"1531_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112027","volume":"123","author":"K Vaghasiya","year":"2021","unstructured":"Vaghasiya K, Ray E, Singh R, Jadhav K, Sharma A, Khan R, et al. Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy. Mater Sci Eng, C. 2021;123:112027. https:\/\/doi.org\/10.1016\/j.msec.2021.112027.","journal-title":"Mater Sci Eng, C"},{"key":"1531_CR149","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2014.11.033","volume":"198","author":"J Silva","year":"2015","unstructured":"Silva J, Zupan\u010di\u010d E, Vandermeulen G, Oliveira V, Salgado A, Videira M, et al. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. J Control Release. 2015;198:91\u2013103. https:\/\/doi.org\/10.1016\/j.jconrel.2014.11.033.","journal-title":"J Control Release"},{"issue":"4","key":"1531_CR150","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1021\/acs.molpharmaceut.9b00065","volume":"16","author":"X Zang","year":"2019","unstructured":"Zang X, Zhang X, Zhao X, Hu H, Qiao M, Deng Y, et al. Targeted delivery of miRNA 155 to tumor-associated macrophages for tumor immunotherapy. Mol Pharm. 2019;16(4):1714\u201322. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00065.","journal-title":"Mol Pharm"},{"key":"1531_CR151","volume":"3","author":"H Sun","year":"2014","unstructured":"Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther. 2014;3:e182.","journal-title":"Mol Ther"},{"key":"1531_CR152","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2022.0024","author":"T Zamay","year":"2022","unstructured":"Zamay T, Starkov A, Kolovskaya O, Zamay G, Veprintsev D, Luzan N, et al. Nucleic acid aptamers increase the anticancer efficiency and reduce the toxicity of Cisplatin-Arabinogalactan conjugates In Vivo. Nucleic Acid Ther. 2022. https:\/\/doi.org\/10.1089\/nat.2022.0024.","journal-title":"Nucleic Acid Ther"},{"key":"1531_CR153","doi-asserted-by":"publisher","DOI":"10.2174\/1567201817666200106104332","author":"G Shrivastava","year":"2020","unstructured":"Shrivastava G, Bakshi H, Aljabali A, Mishra V, Hakkim F, Charbe N, et al. Nucleic acid aptamer as potential nucleus-targeted drug delivery systems. Curr Drug Deliv. 2020. https:\/\/doi.org\/10.2174\/1567201817666200106104332.","journal-title":"Curr Drug Deliv"},{"key":"1531_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040670","author":"M Rahim","year":"2021","unstructured":"Rahim M, Jan N, Khan S, Shah H, Madni A, Khan A, et al. Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13040670.","journal-title":"Cancers"},{"key":"1531_CR155","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ajps.2019.06.003","volume":"15","author":"R Li","year":"2019","unstructured":"Li R, Peng F, Cai J, Yang D, Zhang P. Redox dual-stimuli responsive drug delivery systems for improving tumor-targeting ability and reducing adverse side effects. Asian J Pharm Sci. 2019;15:311\u201325. https:\/\/doi.org\/10.1016\/j.ajps.2019.06.003.","journal-title":"Asian J Pharm Sci"},{"issue":"7","key":"1531_CR156","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1021\/acsnano.6b02326","volume":"10","author":"H Li","year":"2016","unstructured":"Li H, Du J, Liu J, Du X, Shen S, Zhu Y, et al. Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano. 2016;10(7):6753\u201361. https:\/\/doi.org\/10.1021\/acsnano.6b02326.","journal-title":"ACS Nano"},{"key":"1531_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/gels10070478","author":"C Raffaele","year":"2024","unstructured":"Raffaele C, Anna V, Silvia R, Sabrina M, Orsolina P, Anna C. Stimuli-responsive nanocomposite hydrogels for oral diseases. Gels. 2024. https:\/\/doi.org\/10.3390\/gels10070478.","journal-title":"Gels"},{"key":"1531_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134112","author":"R Pansuriya","year":"2024","unstructured":"Pansuriya R, Patel T, Singh K, Al Ghamdi A, Kasoju N, Kumar A, et al. Self-healable, stimuli-responsive bio-ionic liquid and sodium alginate conjugated hydrogel with tunable Injectability and mechanical properties for the treatment of breast cancer. Int J Biol Macromol. 2024. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.134112.","journal-title":"Int J Biol Macromol"},{"key":"1531_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2024.110202","author":"AK Azad","year":"2024","unstructured":"Azad AK, Sulaiman WMAW, Almoustafa H, Dayoob M, Kumarasamy V, Subramaniyan V, et al. A dataset of microstructure features of electro-hydrodynamically assisted 5-fluorouracil-grafted alginate microbeads and physicochemical properties for effective colon targeted carriers drug delivery. Data Brief. 2024. https:\/\/doi.org\/10.1016\/j.dib.2024.110202.","journal-title":"Data Brief"},{"key":"1531_CR160","doi-asserted-by":"publisher","DOI":"10.9734\/jpri\/2022\/v34i637288","author":"L Sachin","year":"2022","unstructured":"Sachin L, Milind J, Umekar U. (1) Thermosensitive lipid-delivery systems: a review. J Pharm Res Int. 2022. https:\/\/doi.org\/10.9734\/jpri\/2022\/v34i637288.","journal-title":"J Pharm Res Int"},{"key":"1531_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133842","author":"C Chong","year":"2024","unstructured":"Chong C, Weibo Z, Pengjie W, Yan Z, Yinhua Z, Yixuan Li, et al. Thermoresponsive composite nanoparticles based on hydroxybutyl chitosan oligosaccharide: fabrication, stimulus release and cancer therapy. Int J Biol Macromol. 2024. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133842.","journal-title":"Int J Biol Macromol"},{"key":"1531_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116508","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang L, Gao H, Yu C, Gao Y, Peng Q. Nanomaterials-based advanced systems for photothermal\/photodynamic therapy of oral cancer. Eur J Med Chem. 2024. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116508.","journal-title":"Eur J Med Chem"},{"key":"1531_CR163","doi-asserted-by":"publisher","DOI":"10.1080\/01932691.2024.2348512","author":"Wu Shu","year":"2024","unstructured":"Shu Wu, Chen W, Xia C, Lu B, Qiuhua Wu, Guolin Z. pH- and temperature-responsive hollow mesoporous silica nanoparticles for drug encapsulation and delivery. J Dispersion Sci Technol. 2024. https:\/\/doi.org\/10.1080\/01932691.2024.2348512.","journal-title":"J Dispersion Sci Technol"},{"key":"1531_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47026-7","author":"S Ramezanian","year":"2023","unstructured":"Ramezanian S, Moghaddas J, Roghani-Mamaqani H, Rezamand A. Dual pH- and temperature-responsive poly(dimethylaminoethyl methacrylate)-coated mesoporous silica nanoparticles as a smart drug delivery system. Dental Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-47026-7.","journal-title":"Dental Sci Rep"},{"key":"1531_CR165","doi-asserted-by":"publisher","unstructured":"William N, Brown. Enzyme-responsive materials: properties, design, and applications. 2023. https:\/\/doi.org\/10.1021\/bk-2023-1436.ch009.","DOI":"10.1021\/bk-2023-1436.ch009."},{"key":"1531_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2024.215842","author":"Lv Jingxia","year":"2024","unstructured":"Jingxia Lv, Renye Y, Huiyi L, Huan Du, Chang Lu, Cheng Z, et al. Enzyme-activated nanomaterials for MR imaging and tumor therapy. Coord Chem Rev. 2024. https:\/\/doi.org\/10.1016\/j.ccr.2024.215842.","journal-title":"Coord Chem Rev"},{"key":"1531_CR167","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/26\/14\/145102","author":"Y Liu","year":"2015","unstructured":"Liu Y, Ding X, Li J, Luo Z, Hu Y, Liu J, et al. Enzyme responsive drug delivery system based on mesoporous silica nanoparticles for tumor therapy in vivo. Nanotechnology. 2015. https:\/\/doi.org\/10.1088\/0957-4484\/26\/14\/145102.","journal-title":"Nanotechnology"},{"issue":"10","key":"1531_CR168","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1021\/acsnano.7b07214","volume":"11","author":"A Nel","year":"2017","unstructured":"Nel A, Ruoslahti E, Meng H. New insights into \u201cpermeability\u201d as in the enhanced permeability and retention effect of cancer nanotherapeutics. ACS Nano. 2017;11(10):9567\u20139. https:\/\/doi.org\/10.1021\/acsnano.7b07214.","journal-title":"ACS Nano"},{"key":"1531_CR169","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.msec.2015.11.067","volume":"60","author":"F Masood","year":"2016","unstructured":"Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng, C. 2016;60:569\u201378. https:\/\/doi.org\/10.1016\/j.msec.2015.11.067.","journal-title":"Mater Sci Eng, C"},{"key":"1531_CR170","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00432-014-1767-3","volume":"141","author":"R Bazak","year":"2015","unstructured":"Bazak R, Houri M, Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141:769\u201384. https:\/\/doi.org\/10.1007\/s00432-014-1767-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1531_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.01.035","author":"A Marques","year":"2020","unstructured":"Marques A, Costa P, Velho S, Velho S, Amaral M. Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J Control Release. 2020. https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.035.","journal-title":"J Control Release"},{"key":"1531_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112260","volume":"144","author":"L Al-mansoori","year":"2021","unstructured":"Al-mansoori L, Elsinga P, Goda S. Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomed Pharm Biomed Pharmacotherapie. 2021;144:112260. https:\/\/doi.org\/10.1016\/j.biopha.2021.112260.","journal-title":"Biomed Pharm Biomed Pharmacotherapie"},{"issue":"1","key":"1531_CR173","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348.","journal-title":"Adv Drug Deliv Rev"},{"key":"1531_CR174","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho K, Wang X, Nie S, Chen Z, Shin D. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1441.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1531_CR175","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1039\/c5cs00798d","volume":"45","author":"M Karimi","year":"2016","unstructured":"Karimi M, Ghasemi A, Zangabad P, Rahighi R, Basri S, Mirshekari H, et al. Smart micro\/nanoparticles in stimulus-responsive drug\/gene delivery systems. Chem Soc Rev. 2016;45(5):1457\u2013501. https:\/\/doi.org\/10.1039\/c5cs00798d.","journal-title":"Chem Soc Rev"},{"issue":"10","key":"1531_CR176","doi-asserted-by":"publisher","DOI":"10.1002\/marc.201800917","volume":"40","author":"N Deirram","year":"2019","unstructured":"Deirram N, Zhang C, Kermaniyan S, Johnston A, Such G. pH-responsive polymer nanoparticles for drug delivery. Macromol Rapid Commun. 2019;40(10):e1800917. https:\/\/doi.org\/10.1002\/marc.201800917.","journal-title":"Macromol Rapid Commun"},{"key":"1531_CR177","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biomaterials.2016.01.061","volume":"85","author":"M Kanamala","year":"2016","unstructured":"Kanamala M, Wilson W, Yang M, Palmer B, Wu Z. Mechanisms and biomaterials in pH-responsive tumor targeted drug delivery: a review. Biomaterials. 2016;85:152\u201367. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.01.061.","journal-title":"Biomaterials"},{"key":"1531_CR178","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.0c00456","author":"M Aikins","year":"2020","unstructured":"Aikins M, Xu C, Moon J. Engineered nanoparticles for cancer vaccination and immunotherapy. Acc Chem Res. 2020. https:\/\/doi.org\/10.1021\/acs.accounts.0c00456.","journal-title":"Acc Chem Res"},{"key":"1531_CR179","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b11881","author":"T Kang","year":"2019","unstructured":"Kang T, Li Y, Wang Y, Zhu J, Yang L, Huang Y, et al. Modular engineering of targeted dual-drug nano-assembles for cancer chemo-immunotherapy. ACS Appl Mater Interfaces. 2019. https:\/\/doi.org\/10.1021\/acsami.9b11881.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1531_CR180","doi-asserted-by":"publisher","DOI":"10.1080\/08982104.2023.2226216","author":"H Nsairat","year":"2023","unstructured":"Nsairat H, Ibrahim A, Jaber A, Abdelghany S, Atwan R, Shalan N, et al. Liposome bilayer stability: Implications for cholesterol and its alternatives. J Liposome Res. 2023. https:\/\/doi.org\/10.1080\/08982104.2023.2226216.","journal-title":"J Liposome Res"},{"key":"1531_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120571","author":"D Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es D, Cavaco\u2010Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120571.","journal-title":"Int J Pharm"},{"issue":"1","key":"1531_CR182","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/21691401.2023.2247036","volume":"51","author":"S Pande","year":"2023","unstructured":"Pande S. Liposomes for drug delivery: review of the vesicular composition, factors affecting drug release, and drug loading in liposomes. Artif Cells Nanomed Biotechnol. 2023;51(1):428\u201340. https:\/\/doi.org\/10.1080\/21691401.2023.2247036.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1531_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.06.022","author":"N Filipczak","year":"2020","unstructured":"Filipczak N, Pan J, Yalamarty S, Torchilin V. Recent advancements in liposome technology. Adv Drug Deliv Rev. 2020. https:\/\/doi.org\/10.1016\/j.addr.2020.06.022.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"1531_CR184","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/colloids8040042","volume":"8","author":"II Mota D\u00edaz","year":"2024","unstructured":"Mota D\u00edaz II, Douda J, Garc\u00eda L\u00f3pez P, et al. Co-encapsulation of paclitaxel and doxorubicin in liposomes layer by layer. Colloids Interfaces. 2024;8(4):42. https:\/\/doi.org\/10.3390\/colloids8040042.","journal-title":"Colloids Interfaces."},{"issue":"5","key":"1531_CR185","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1021\/mp5000373","volume":"11","author":"Y Liu","year":"2014","unstructured":"Liu Y, Fang J, Kim Y-J, et al. Codelivery of doxorubicin and paclitaxel via cross-linked multilamellar liposomes enables synergistic antitumor activity. Mol Pharm. 2014;11(5):1651\u201361. https:\/\/doi.org\/10.1021\/mp5000373.","journal-title":"Mol Pharm"},{"key":"1531_CR186","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biomaterials.2016.03.040","volume":"93","author":"E Chuang","year":"2016","unstructured":"Chuang E, Lin C, Chen K, Wan D, Lin K, Ho Y, et al. A FRET-guided, NIR-responsive bubble-generating liposomal system for in vivo targeted therapy with spatially and temporally precise controlled release. Biomaterials. 2016;93:48\u201359. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.03.040.","journal-title":"Biomaterials"},{"key":"1531_CR187","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/21691401.2017.1304403","volume":"46","author":"F Haghiralsadat","year":"2018","unstructured":"Haghiralsadat F, Amoabediny G, Helder M, Naderinezhad S, Sheikhha M, Forouzanfar T, et al. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery. Artif Cells Nanomed Biotechnol. 2018;46:169\u201377. https:\/\/doi.org\/10.1080\/21691401.2017.1304403.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"14","key":"1531_CR188","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.3390\/ijms241411686","volume":"24","author":"V Kozik","year":"2023","unstructured":"Kozik V, Pentak D, Pa\u017adzior M, et al. From design to study of liposome-driven drug release part 1: impact of temperature and pH on environment. Int J Mol Sci. 2023;24(14):11686. https:\/\/doi.org\/10.3390\/ijms241411686.","journal-title":"Int J Mol Sci"},{"key":"1531_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2024.100258","volume":"7","author":"Z Liu","year":"2024","unstructured":"Liu Z, Liu Y, Zixuan Wu, Liu B, et al. Research on the loading and release kinetics of vincristine sulfate liposomes and their anti-breast cancer activity. Int J Pharm: X. 2024;7:100258. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100258.","journal-title":"Int J Pharm: X"},{"issue":"3","key":"1531_CR190","first-page":"256","volume":"25","author":"J Wang","year":"2008","unstructured":"Wang J, Sun Y. The relationship between drug carrying ability of liposomes and phosphatidylcholines. Fine Chem-Dalian-. 2008;25(3):256.","journal-title":"Fine Chem-Dalian-"},{"issue":"1\u20132","key":"1531_CR191","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijpharm.2010.12.005","volume":"405","author":"J Parmentier","year":"2011","unstructured":"Parmentier J, Becker M, Heintz U, Fricker G. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. Int J Pharm. 2011;405(1\u20132):210\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.12.005.","journal-title":"Int J Pharm"},{"issue":"24","key":"1531_CR192","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.3390\/ijms21249559","volume":"21","author":"K Juszkiewicz","year":"2020","unstructured":"Juszkiewicz K, Sikorski AF, et al. Building blocks for liposomal delivery systems. Int J Mol Sci. 2020;21(24):9559. https:\/\/doi.org\/10.3390\/ijms21249559.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"1531_CR193","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.09.047","volume":"551","author":"H Farzaneh","year":"2018","unstructured":"Farzaneh H, Nik ME, et al. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: from preparation to therapy. Int J Pharm. 2018;551(1\u20132):300\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.09.047.","journal-title":"Int J Pharm"},{"key":"1531_CR194","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032643","author":"S Wang","year":"2023","unstructured":"Wang S, Chen Y, Guo J, Huang Q. Liposomes for tumor-targeted therapy: a review. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032643.","journal-title":"Int J Mol Sci"},{"key":"1531_CR195","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1080\/1061186X.2018.1527337","volume":"27","author":"K Ahmed","year":"2018","unstructured":"Ahmed K, Hussein S, Ali A, Korma S, Qiu L, Chen J. Liposome: composition, characterization, preparation, and recent innovation in clinical applications. J Drug Target. 2018;27:742\u201361. https:\/\/doi.org\/10.1080\/1061186X.2018.1527337.","journal-title":"J Drug Target"},{"issue":"2","key":"1531_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23020288","volume":"23","author":"N Lamichhane","year":"2018","unstructured":"Lamichhane N, Udayakumar TS, et al. Liposomes: clinical applications and potential for image-guided drug delivery. Molecules. 2018;23(2):288. https:\/\/doi.org\/10.3390\/molecules23020288.","journal-title":"Molecules"},{"issue":"5","key":"1531_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, et al. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09394.","journal-title":"Heliyon"},{"key":"1531_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2020.111193","volume":"194","author":"M Farid","year":"2020","unstructured":"Farid M, Faber T, Dietrich D, Lamprecht A. Cell membrane fusing liposomes for cytoplasmic delivery in brain endothelial cells. Colloids Surf B Biointerfaces. 2020;194:111193. https:\/\/doi.org\/10.1016\/j.colsurfb.2020.111193.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1531_CR199","doi-asserted-by":"publisher","DOI":"10.1063\/5.0029860","author":"M Aronson","year":"2021","unstructured":"Aronson M, Medina S, Mitchell M. Peptide-functionalized liposomes for receptor targeted cancer therapy. APL Bioeng. 2021. https:\/\/doi.org\/10.1063\/5.0029860.","journal-title":"APL Bioeng"},{"issue":"4","key":"1531_CR200","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1021\/mp800215d","volume":"6","author":"C Surace","year":"2009","unstructured":"Surace C, Arpicco S, Dufa\u00ff-Wojcicki A, Marsaud V, Bouclier C, Clay D, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol Pharm. 2009;6(4):1062\u201373. https:\/\/doi.org\/10.1021\/mp800215d.","journal-title":"Mol Pharm"},{"key":"1531_CR201","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ijpharm.2019.05.043","volume":"565","author":"T Yoshikawa","year":"2019","unstructured":"Yoshikawa T, Mori Y, Feng H, Phan K, Kishimura A, Kang J, et al. Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect. Int J Pharm. 2019;565:481\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.043.","journal-title":"Int J Pharm"},{"issue":"8","key":"1531_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080771","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771. https:\/\/doi.org\/10.3390\/jpm11080771.","journal-title":"J Pers Med"},{"issue":"4","key":"1531_CR203","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2967\/jnumed.115.166173","volume":"57","author":"M Bolkestein","year":"2016","unstructured":"Bolkestein M, de Blois E, Koelewijn SJ, Eggermont AMM, et al. Investigation of factors determining the enhanced permeability and retention effect in subcutaneous xenografts. J Nucl Med. 2016;57(4):601\u20137. https:\/\/doi.org\/10.2967\/jnumed.115.166173.","journal-title":"J Nucl Med"},{"key":"1531_CR204","doi-asserted-by":"publisher","first-page":"10082","DOI":"10.3390\/ijms241210082","volume":"24","author":"J Kim","year":"2023","unstructured":"Kim J, Cho H, Lim D-K, et al. Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors. Int J Mol Sci. 2023;24:10082. https:\/\/doi.org\/10.3390\/ijms241210082.","journal-title":"Int J Mol Sci"},{"key":"1531_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2020.127127","volume":"328","author":"L Chotphruethipong","year":"2020","unstructured":"Chotphruethipong L, Battino M, Benjakul S. Effect of stabilizing agents on characteristics, antioxidant activities, and stability of liposome loaded with hydrolyzed collagen from defatted Asian sea bass skin. Food Chem. 2020;328:127127. https:\/\/doi.org\/10.1016\/j.foodchem.2020.127127.","journal-title":"Food Chem"},{"key":"1531_CR206","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030633","author":"D Jbara-Agbaria","year":"2022","unstructured":"Jbara-Agbaria D, Blondzik S, Burger-Kentischer A, Agbaria M, Nordling-David M, Giterman A, et al. Liposomal siRNA formulations for the treatment of herpes simplex virus-1: in vitro characterization of physicochemical properties and activity, and in vivo biodistribution and toxicity studies. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14030633.","journal-title":"Pharmaceutics"},{"key":"1531_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040479","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Salmon H, Distasio N, Do H, Scherman D, Alhareth K, et al. Viscous core liposomes increase siRNA encapsulation and provides gene inhibition when slightly positively charged. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13040479.","journal-title":"Pharmaceutics"},{"key":"1531_CR208","doi-asserted-by":"publisher","DOI":"10.3390\/polym13071027","author":"V Leo","year":"2021","unstructured":"Leo V, Milano F, Agostiano A, Catucci L. Recent advancements in polymer\/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polymers. 2021. https:\/\/doi.org\/10.3390\/polym13071027.","journal-title":"Polymers"},{"key":"1531_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110952","volume":"134","author":"S Reis","year":"2020","unstructured":"Reis S, Silva J, Garcia-Fossa F, Leite E, Malachias \u00c2, Pound-Lana G, et al. Mechanistic insights into the intracellular release of doxorubicin from ph-sensitive liposomes. Biomed Pharmacother. 2020;134:110952. https:\/\/doi.org\/10.1016\/j.biopha.2020.110952.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1531_CR210","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2174\/1389201016666150206105149","volume":"16","author":"B Mukherjee","year":"2015","unstructured":"Mukherjee B, Mondal L, Chakraborty S, Paul P, Choudhury A, Bhattacharya S, et al. Size-dependent variations of phospholipid-based vesicular drug carriers in systemic drug activity. Curr Pharm Biotechnol. 2015;16(4):380\u201391. https:\/\/doi.org\/10.2174\/1389201016666150206105149.","journal-title":"Curr Pharm Biotechnol"},{"key":"1531_CR211","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ijpharm.2019.06.013","volume":"566","author":"P Singh","year":"2019","unstructured":"Singh P, Bodycomb J, Travers B, Tatarkiewicz K, Travers S, Matyas G, et al. Particle size analyses of polydisperse liposome formulations with a novel multispectral advanced nanoparticle tracking technology. Int J Pharm. 2019;566:680\u20136. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.06.013.","journal-title":"Int J Pharm"},{"key":"1531_CR212","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-3-662-49320-5_12","volume-title":"Liposome-based drug delivery systems","author":"W Gao","year":"2021","unstructured":"Gao W. Preparation and evaluation of folate receptor mediated targeting liposomes. In: Liposome-based drug delivery systems. Berlin, Heidelberg: Springer, Berlin Heidelberg; 2021. p. 167\u201378."},{"key":"1531_CR213","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41419-024-06776-6","volume":"15","author":"W Yang","year":"2024","unstructured":"Yang W, Sun Q, Zhang X, Zheng L, Yang X, et al. A novel doxorubicin\/CTLA-4 blocker co-loaded drug delivery system improves the efficacy and safety in antitumor therapy. Cell Death Dis. 2024;15:386.","journal-title":"Cell Death Dis"},{"key":"1531_CR214","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40779-023-00455-x","volume":"10","author":"G-L Ma","year":"2023","unstructured":"Ma G-L, Lin W-F. Immune checkpoint inhibition mediated by liposomal nanomedicine for cancer therapy. Mil Med Res. 2023;10:20. https:\/\/doi.org\/10.1186\/s40779-023-00455-x.","journal-title":"Mil Med Res"},{"key":"1531_CR215","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.msec.2018.04.011","volume":"89","author":"W Yang","year":"2018","unstructured":"Yang W, Hu Q, Xu Y, Liu H, Zhong L. Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng, C. 2018;89:328\u201335. https:\/\/doi.org\/10.1016\/j.msec.2018.04.011.","journal-title":"Mater Sci Eng, C"},{"issue":"1\u20132","key":"1531_CR216","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/J.IJPHARM.2006.02.027","volume":"316","author":"J Wu","year":"2006","unstructured":"Wu J, Liu Q, Lee R. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm. 2006;316(1\u20132):148\u201353. https:\/\/doi.org\/10.1016\/J.IJPHARM.2006.02.027.","journal-title":"Int J Pharm"},{"key":"1531_CR217","doi-asserted-by":"publisher","DOI":"10.1166\/JNN.2009.450","author":"G Zhai","year":"2009","unstructured":"Zhai G, Zhai G, Wu J, Xiang G, Xiang G, Mao W, et al. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol. 2009. https:\/\/doi.org\/10.1166\/JNN.2009.450.","journal-title":"J Nanosci Nanotechnol"},{"key":"1531_CR218","doi-asserted-by":"publisher","DOI":"10.3109\/08982100009029385","author":"W Guo","year":"2000","unstructured":"Guo W, Lee T, Sudimack JJ, Lee JR. Receptor-specific delivery of liposomes via folate-Peg-Chol. J Liposome Res. 2000. https:\/\/doi.org\/10.3109\/08982100009029385.","journal-title":"J Liposome Res"},{"issue":"2","key":"1531_CR219","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2003.12.028","volume":"213","author":"M Turk","year":"2004","unstructured":"Turk M, Waters DJ, Low P. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 2004;213(2):165\u201372.","journal-title":"Cancer Lett"},{"issue":"2","key":"1531_CR220","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0005-2736(94)00235-H","volume":"1233","author":"RJ Lee","year":"1995","unstructured":"Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233(2):134\u201344.","journal-title":"Biochim Biophys Acta"},{"key":"1531_CR221","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.colsurfb.2018.07.013","volume":"170","author":"Z Soe","year":"2018","unstructured":"Soe Z, Thapa R, Ou W, Gautam M, Nguyen H, Jin S, et al. Folate receptor-mediated delivery of celastrol and irinotecan in combination with liposomes for effective chemotherapy. Colloids Surf B Biointerfaces. 2018;170:718\u201328.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"4","key":"1531_CR222","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2174\/1389201016666150118135107","volume":"16","author":"A Chaudhury","year":"2015","unstructured":"Chaudhury A, Das S. Folate receptor-targeted liposomes encapsulating anti-cancer drugs. Curr Pharm Biotechnol. 2015;16(4):333\u201343.","journal-title":"Curr Pharm Biotechnol"},{"issue":"1-3","key":"1531_CR223","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0168-3659(02)00017-2","volume":"80","author":"G Shi","year":"2002","unstructured":"Shi G, Guo W, Stephenson S, Lee RJ. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes. J Control Release. 2002;80(1\u20133):309\u201319.","journal-title":"J Control Release"},{"issue":"5","key":"1531_CR224","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1166\/jbn.2013.1587","volume":"9","author":"Z He","year":"2013","unstructured":"He Z, Yu Y, Zhang Y, Yan Y-D, Zheng Yu, He J, et al. Gene delivery with active targeting of ovarian cancer cells via folate receptor alpha. J Biomed Nanotechnol. 2013;9(5):833\u201344. https:\/\/doi.org\/10.1166\/jbn.2013.1587.","journal-title":"J Biomed Nanotechnol"},{"issue":"1","key":"1531_CR225","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ab.2004.05.034","volume":"332","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Guo L, Roeske R, Antony A, Jayaram H. Pteroyl-gamma-glutamate-cysteine synthesis and its application in folate receptor-mediated cancer cell targeting using folate-tethered liposomes. Anal Biochem. 2004;332(1):168\u201377.","journal-title":"Anal Biochem"},{"issue":"4","key":"1531_CR226","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1021\/bc020089t","volume":"14","author":"C Leamon","year":"2003","unstructured":"Leamon C, Cooper S, Hardee G. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem. 2003;14(4):738\u201347.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"1531_CR227","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/1535-7163.MCT-05-0543","volume":"5","author":"H Shmeeda","year":"2006","unstructured":"Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther. 2006;5(4):818\u201324.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1531_CR228","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17425247.2022.2083106","volume":"19","author":"M-J Solmaz","year":"2022","unstructured":"Solmaz M-J, Somayeh M, Masoud F, Muhammad S, Yousef F, Fatemeh A, et al. Transferrin receptor-mediated liposomal drug delivery: recent trends in targeted therapy of cancer. Expert Opin Drug Deliv. 2022;19(6):685\u2013705. https:\/\/doi.org\/10.1080\/17425247.2022.2083106.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"1531_CR229","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1166\/JNN.2020.16955","volume":"20","author":"W Yuanyuan","year":"2020","unstructured":"Yuanyuan W, Yining Y, Yibin Yu, Jinyu Li, Weisan P, Xinggang Y, et al. Transferrin-modified dioscin-loaded PEGylated liposomes: characterization and in vitro antitumor effect. J Nanosci Nanotechnol. 2020;20(3):1321\u201331. https:\/\/doi.org\/10.1166\/JNN.2020.16955.","journal-title":"J Nanosci Nanotechnol"},{"issue":"2","key":"1531_CR230","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/JIN2.56","volume":"4","author":"I Sakpakdeejaroen","year":"2019","unstructured":"Sakpakdeejaroen I, Somani S, Laskar P, Mullin M, Duf\u00e8s C. Transferrin-bearing liposomes entrapping plumbagin for targeted cancer therapy. J Interdiscip Nanomed. 2019;4(2):54\u201371. https:\/\/doi.org\/10.1002\/JIN2.56.","journal-title":"J Interdiscip Nanomed."},{"issue":"8","key":"1531_CR231","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/J.XPHS.2019.11.013","volume":"109","author":"F Jia","year":"2020","unstructured":"Jia F, Wenpan L, Xiu X, Dawei C, Haiyang H. Transferrin-modified nanoliposome codelivery strategies for enhancing cancer therapy. J Pharm Sci. 2020;109(8):2426\u201336. https:\/\/doi.org\/10.1016\/J.XPHS.2019.11.013.","journal-title":"J Pharm Sci"},{"key":"1531_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.04.009","volume":"57","author":"Q Li","year":"2015","unstructured":"Li Q, Tang Q, Zhang P, Wang Z, Zhao T, Zhou J, et al. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes. Biomaterials. 2015;57:1\u201311. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.04.009.","journal-title":"Biomaterials"},{"key":"1531_CR233","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1517\/17425247.5.9.1003","volume":"5","author":"V Torchilin","year":"2008","unstructured":"Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv. 2008;5:1003\u201325. https:\/\/doi.org\/10.1517\/17425247.5.9.1003.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"1531_CR234","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/J.JCONREL.2004.08.007","volume":"100","author":"A Lukyanov","year":"2004","unstructured":"Lukyanov A, Elbayoumi T, Chakilam A, Torchilin V. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release. 2004;100(1):135\u201344. https:\/\/doi.org\/10.1016\/J.JCONREL.2004.08.007.","journal-title":"J Control Release"},{"key":"1531_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.09.055","author":"J Sonju","year":"2020","unstructured":"Sonju J, Dahal A, Singh S, Jois S. Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. J Control Release. 2020. https:\/\/doi.org\/10.1016\/j.jconrel.2020.09.055.","journal-title":"J Control Release"},{"issue":"19","key":"1531_CR236","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1016\/j.biomaterials.2014.03.017","volume":"35","author":"Z Yang","year":"2014","unstructured":"Yang Z, Li J, Wang Z, Dong D, Qi X. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35(19):5226\u201339. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.03.017.","journal-title":"Biomaterials"},{"key":"1531_CR237","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.2147\/IJN.S129946","volume":"12","author":"W Xu","year":"2017","unstructured":"Xu W, Liu D, Cao Y, Wang X. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers. Int J Nanomedicine. 2017;12:6461\u201370. https:\/\/doi.org\/10.2147\/IJN.S129946.","journal-title":"Int J Nanomedicine"},{"key":"1531_CR238","doi-asserted-by":"publisher","first-page":"9246","DOI":"10.1016\/j.biomaterials.2012.09.027","volume":"33","author":"T Jiang","year":"2012","unstructured":"Jiang T, Zhang Z, Zhang Y, Lv H, Zhou J, Li C, et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials. 2012;33:9246\u201358. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.09.027.","journal-title":"Biomaterials"},{"issue":"1","key":"1531_CR239","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbrc.2015.11.084","volume":"469","author":"T Iwama","year":"2016","unstructured":"Iwama T, Uchida T, Sawada Y, Tsuchiya N, Sugai S, Fujinami N, et al. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochem Biophys Res Commun. 2016;469(1):138\u201343. https:\/\/doi.org\/10.1016\/j.bbrc.2015.11.084.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1531_CR240","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1039\/c6bm00898d","volume":"5","author":"X Jia","year":"2017","unstructured":"Jia X, Han Q, Wang Z, Qian Y, Jia Y, Wang W, et al. Targeting peptide-functionalized liposomes toward aminopeptidase N for precise tumor diagnosis and therapy. Biomater Sci. 2017;5(3):417\u201321. https:\/\/doi.org\/10.1039\/c6bm00898d.","journal-title":"Biomater Sci"},{"issue":"30","key":"1531_CR241","doi-asserted-by":"publisher","first-page":"16792","DOI":"10.1021\/acsami.5b04596","volume":"7","author":"Y Liu","year":"2015","unstructured":"Liu Y, Mei L, Yu Q, Xu C, Qiu Y, Yang Y, et al. Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma. ACS Appl Mater Interf. 2015;7(30):16792\u2013801. https:\/\/doi.org\/10.1021\/acsami.5b04596.","journal-title":"ACS Appl Mater Interf"},{"issue":"12","key":"1531_CR242","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1039\/c5bm00161g","volume":"3","author":"J Cao","year":"2015","unstructured":"Cao J, Wang R, Gao N, Li M, Tian X, Yang W, et al. A7RC peptide modified paclitaxel liposomes dually target breast cancer. Biomater Sci. 2015;3(12):1545\u201354. https:\/\/doi.org\/10.1039\/c5bm00161g.","journal-title":"Biomater Sci"},{"issue":"2","key":"1531_CR243","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.canlet.2008.05.009","volume":"270","author":"Y Katanasaka","year":"2008","unstructured":"Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, et al. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett. 2008;270(2):260\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2008.05.009.","journal-title":"Cancer Lett"},{"key":"1531_CR244","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/aps.2017.10","volume":"38","author":"X Kang","year":"2017","unstructured":"Kang X, Wang H, Peng H, Chen B, Zhang W, Wu A, et al. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacol Sin. 2017;38:885\u201396. https:\/\/doi.org\/10.1038\/aps.2017.10.","journal-title":"Acta Pharmacol Sin"},{"issue":"31","key":"1531_CR245","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1016\/j.biomaterials.2012.07.022","volume":"33","author":"L Locke","year":"2012","unstructured":"Locke L, Mayo M, Yoo A, Williams M, Berr S. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. Biomaterials. 2012;33(31):7785\u201393. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.07.022.","journal-title":"Biomaterials"},{"key":"1531_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108148","volume":"101","author":"J Yu","year":"2021","unstructured":"Yu J, Wang S, Qi J, Yu Z, Xian Y, Liu W, et al. Mannose-modified liposome designed for epitope peptide drug delivery in cancer immunotherapy. Int Immunopharmacol. 2021;101:108148. https:\/\/doi.org\/10.1016\/j.intimp.2021.108148.","journal-title":"Int Immunopharmacol"},{"key":"1531_CR247","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.2147\/IJN.S275670","volume":"15","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Wang H, Yang Y, Jia W, Su T, Che Y, et al. Mannose-modified liposome co-delivery of human papillomavirus type 16 E7 peptide and CpG oligodeoxynucleotide adjuvant enhances antitumor activity against established large TC-1 grafted tumors in mice. Int J Nanomedicine. 2020;15:9571\u201386.","journal-title":"Int J Nanomedicine"},{"key":"1531_CR248","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/02652048.2017.1339739","volume":"34","author":"M Xiong","year":"2017","unstructured":"Xiong M, Lei Q, You X, Gao T, Song X, Xia Y, et al. Mannosylated liposomes improve the therapeutic effects of paclitaxel in colon cancer models. J Microencapsul. 2017;34:513\u201321.","journal-title":"J Microencapsul"},{"issue":"10","key":"1531_CR249","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1021\/acsabm.9b00705","volume":"2","author":"D Kim","year":"2019","unstructured":"Kim D, Kim M, Park H, Kim K, Kim D. Anti-MUC1\/CD44 dual-aptamer-conjugated liposomes for cotargeting breast cancer cells and cancer stem cells. ACS Appl Biomater. 2019;2(10):4622\u201333. https:\/\/doi.org\/10.1021\/acsabm.9b00705.","journal-title":"ACS Appl Biomater"},{"issue":"7","key":"1531_CR250","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1021\/bc5004313","volume":"26","author":"W Alshaer","year":"2015","unstructured":"Alshaer W, Hillaireau H, Vergnaud J, Ismail S, Fattal E. Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjug Chem. 2015;26(7):1307\u201313. https:\/\/doi.org\/10.1021\/bc5004313.","journal-title":"Bioconjug Chem"},{"key":"1531_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109072","volume":"117","author":"X Li","year":"2019","unstructured":"Li X, Wu X, Yang H, Li L, Ye Z, Rao Y. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer. Biomed Pharmacother. 2019;117:109072. https:\/\/doi.org\/10.1016\/j.biopha.2019.109072.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1531_CR252","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1166\/jbn.2019.2751","volume":"15","author":"S Yu","year":"2019","unstructured":"Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, et al. Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. J Biomed Nanotechnol. 2019;15(6):1135\u201348. https:\/\/doi.org\/10.1166\/jbn.2019.2751.","journal-title":"J Biomed Nanotechnol"},{"issue":"4","key":"1531_CR253","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1039\/c5bm00479a","volume":"4","author":"G Moku","year":"2016","unstructured":"Moku G, Gulla S, Nimmu N, Khalid S, Chaudhuri A. Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes. Biomater Sci. 2016;4(4):627\u201338. https:\/\/doi.org\/10.1039\/c5bm00479a.","journal-title":"Biomater Sci"},{"issue":"1","key":"1531_CR254","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1021\/acs.bioconjchem.7b00551","volume":"29","author":"M Miyazaki","year":"2017","unstructured":"Miyazaki M, Yuba E, Hayashi H, Harada A, Kono K. Hyaluronic acid-based pH-sensitive polymer-modified liposomes for cell-specific intracellular drug delivery systems. Bioconjug Chem. 2017;29(1):44\u201355. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00551.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"1531_CR255","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1016\/j.biomaterials.2013.01.030","volume":"34","author":"R Mo","year":"2013","unstructured":"Mo R, Sun Q, Li N, Zhang C. Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids. Biomaterials. 2013;34(11):2773\u201386. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.01.030.","journal-title":"Biomaterials"},{"issue":"9","key":"1531_CR256","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1039\/c8nr06218h","volume":"11","author":"M Chen","year":"2019","unstructured":"Chen M, Song F, Liu Y, Tian J, Liu C, Li R, et al. A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer. Nanoscale. 2019;11(9):3814\u201326. https:\/\/doi.org\/10.1039\/c8nr06218h.","journal-title":"Nanoscale"},{"key":"1531_CR257","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.colsurfb.2016.11.042","volume":"151","author":"Y Fan","year":"2017","unstructured":"Fan Y, Chen C, Huang Y, Zhang F, Lin G. Study of the pH-sensitive mechanism of tumor-targeting liposomes. Colloids Surf B Biointerfaces. 2017;151:19\u201325. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.11.042.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1531_CR258","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jconrel.2015.12.006","volume":"222","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Ren W, Zhong T, Zhang S, Huang D, Guo Y, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J Control Release. 2016;222:56\u201366. https:\/\/doi.org\/10.1016\/j.jconrel.2015.12.006.","journal-title":"J Control Release"},{"issue":"1-2","key":"1531_CR259","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ijpharm.2017.06.069","volume":"528","author":"T Tran","year":"2017","unstructured":"Tran T, Nguyen H, Le N, Tran T, Lee J, Ku S, et al. Engineering of multifunctional temperature-sensitive liposomes for synergistic photothermal, photodynamic, and chemotherapeutic effects. Int J Pharm. 2017;528(1\u20132):692\u2013704. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.06.069.","journal-title":"Int J Pharm"},{"key":"1531_CR260","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jconrel.2016.10.030","volume":"243","author":"Z Deng","year":"2016","unstructured":"Deng Z, Xiao Y, Pan M, Li F, Duan W, Meng L, et al. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound. J Control Release. 2016;243:333\u201341. https:\/\/doi.org\/10.1016\/j.jconrel.2016.10.030.","journal-title":"J Control Release"},{"issue":"18","key":"1531_CR261","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1016\/j.biomaterials.2012.03.018","volume":"33","author":"W Al-Jamal","year":"2012","unstructured":"Al-Jamal W, Al-Ahmady Z, Kostarelos K. Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia. Biomaterials. 2012;33(18):4608\u201317. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.03.018.","journal-title":"Biomaterials"},{"issue":"27","key":"1531_CR262","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1021\/acs.bioconjchem.6b00603","volume":"2016","author":"Y Jin","year":"2016","unstructured":"Jin Y, Liang X, An Y, Dai Z. Microwave-triggered smart drug release from liposomes co-encapsulating doxorubicin and salt for local combined hyperthermia and chemotherapy of cancer. Bioconjug Chem. 2016;2016(27):2931\u201342.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"1531_CR263","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1021\/acsami.8b22748","volume":"11","author":"Y Dai","year":"2019","unstructured":"Dai Y, Su J, Wu K, Ma W, Wang B, Li M, et al. Multifunctional thermosensitive liposomes based on natural phase-change material: near-infrared light-triggered drug release and multimodal imaging-guided cancer combination therapy. ACS Appl Mater Interfaces. 2019;11(11):10540\u201353. https:\/\/doi.org\/10.1021\/acsami.8b22748.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"1531_CR264","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2009.10.002","volume":"142","author":"P Pradhan","year":"2010","unstructured":"Pradhan P, Giri J, Rieken F, Koch C, Mykhaylyk O, D\u00f6blinger M, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release. 2010;142(1):108\u201321. https:\/\/doi.org\/10.1016\/j.jconrel.2009.10.002.","journal-title":"J Control Release"},{"key":"1531_CR265","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.0c03564","author":"L Kou","year":"2020","unstructured":"Kou L, Sun R, Jiang X, Lin X, Huang H, Bao S, et al. Tumor microenvironment-responsive multistaged liposome induces apoptosis and ferroptosis by amplifying oxidative stress for enhanced cancer therapy. ACS Appl Mater Interfaces. 2020. https:\/\/doi.org\/10.1021\/acsami.0c03564.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"4","key":"1531_CR266","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1021\/nn300524f","volume":"6","author":"L Zhu","year":"2012","unstructured":"Zhu L, Kate P, Torchilin V. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano. 2012;6(4):3491\u20138. https:\/\/doi.org\/10.1021\/nn300524f.","journal-title":"ACS Nano"},{"key":"1531_CR267","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.2567","author":"J Shen","year":"2022","unstructured":"Shen J, Li R, Yan J, Du J, Wei J, Zhu S, et al. A phase II study to evaluate the safety and efficacy of radiotherapy combined with irinotecan liposome followed by camrelizumab and apatinib for advanced solid tumors that failed standard treatments. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.2567.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1531_CR268","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1089\/10430349950016357","volume":"10","author":"L Xu","year":"1999","unstructured":"Xu L, Pirollo K, Tang W, Rait A, Chang E. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10(18):2941\u201352. https:\/\/doi.org\/10.1089\/10430349950016357.","journal-title":"Hum Gene Ther"},{"key":"1531_CR269","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111054","author":"Z Gu","year":"2020","unstructured":"Gu Z, Silva C, Maaden K, Ossendorp F, Cruz L. Liposome-based drug delivery systems in cancer immunotherapy. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12111054.","journal-title":"Pharmaceutics"},{"key":"1531_CR270","doi-asserted-by":"publisher","DOI":"10.1039\/d1tb00256b","author":"Q Su","year":"2021","unstructured":"Su Q, Wang C, Song H, Zhang C, Liu J, Huang P, et al. Co-delivery of anionic epitope\/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy. J Mater Chem B. 2021. https:\/\/doi.org\/10.1039\/d1tb00256b.","journal-title":"J Mater Chem B"}],"container-title":["BioMedical Engineering OnLine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12938-026-01531-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12938-026-01531-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12938-026-01531-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:02:14Z","timestamp":1771596134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12938-026-01531-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":270,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1186\/s12938-026-01531-8","relation":{},"ISSN":["1475-925X"],"issn-type":[{"value":"1475-925X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}